Douer D, Shaked N, Ramot B
Institute of Hematology, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Clin Exp Immunol. 1987 Sep;69(3):660-7.
Patients with untreated active Hodgkin's disease (HD) have a defect in cell-mediated immunity. After therapy many HD patients still have long lasting abnormalities in T cell number and function. We examined whether NK activity is also permanently impaired in HD patients in remission. The mean NK activity of peripheral blood lymphocytes from 42 patients who were disease-free for 6-150 months was not different from that of healthy controls. Augmentation of NK activity after treatment of the cells by interferon in vitro was equal for patients and controls. Normal NK activity in HD in remission was independent of disease stage, age, remission duration and mode of therapy. Measuring PHA-induced lymphocyte proliferation and NK activity simultaneously demonstrates that patients with impaired cell-mediated immunity do not have concomitant reduction of NK activity. We conclude that NK activity in HD in remission is independent of decreased T cell mediated immunity. In addition, NK is resistant to long term suppression by the chemotherapy and radiation protocols that are used in HD.
未经治疗的活动性霍奇金病(HD)患者存在细胞介导免疫缺陷。治疗后,许多HD患者的T细胞数量和功能仍长期存在异常。我们研究了缓解期HD患者的自然杀伤(NK)活性是否也受到永久性损害。42例无病6至150个月患者外周血淋巴细胞的平均NK活性与健康对照者无异。体外使用干扰素处理细胞后,患者和对照者的NK活性增强程度相同。缓解期HD患者的正常NK活性与疾病分期、年龄、缓解持续时间和治疗方式无关。同时测量PHA诱导的淋巴细胞增殖和NK活性表明,细胞介导免疫受损的患者其NK活性并未同时降低。我们得出结论,缓解期HD患者的NK活性与T细胞介导的免疫降低无关。此外,NK对HD中使用的化疗和放疗方案的长期抑制具有抗性。